TY  - GEN
AU  - Sattar,Naveed
AU  - Fitchett,David
AU  - Hantel,Stefan
AU  - George,Jyothis T
AU  - Zinman,Bernard
TI  - Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
SN  - 1432-0428
PY  - 2019///0128
KW  - Adipose Tissue
KW  - metabolism
KW  - Asian People
KW  - Aspartate Aminotransferases
KW  - Benzhydryl Compounds
KW  - therapeutic use
KW  - Diabetes Mellitus, Type 2
KW  - drug therapy
KW  - Female
KW  - Glucosides
KW  - Humans
KW  - Hypoglycemic Agents
KW  - Liver
KW  - drug effects
KW  - Male
KW  - Non-alcoholic Fatty Liver Disease
KW  - Research Design
KW  - Sodium-Glucose Transporter 2
KW  - Sodium-Glucose Transporter 2 Inhibitors
KW  - Sulfonylurea Compounds
KW  - Time Factors
KW  - Transaminases
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1007/s00125-018-4702-3
ER  -